Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.

Grifols' commitment to Alzheimer's disease research began more than 15 years ago, when the company began exploring the potential of plasma therapies to treat this devastating neurodegenerative disease. The AMBAR trial (Alzheimer Management by Albumin Replacement) represents one of our most ambitious clinical trials to date.